ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2304

Differential Association of IRAK1 and MECP2 with Specific Systemic Sclerosis Phenotypes

F. David Carmona1, M.C. Cénit1, L.M. Díaz-Gallo1, Carmen P. Simeón2, Patricia Carreira3, the Spanish Scleroderma Group4, Nicolas Hunzelmann5, Gabriela Riemekasten6, Torsten Witte7, Alexander Kreuter8, Jörg HW Distler9, Paul Shiels10, Jacob M. van Laar11, Annemie Schuerwegh12, Madelon C. Vonk13, Alexandre Voskuyl14, Carmen Fonseca15, Christopher Denton16, Ariane Herrick17, Frank C. Arnett18, Filemon K. Tan18, Shervin Assassi18, T.R.D.J. Radstake19, Maureen D. Mayes18 and Javier Martin1, 1Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, Armilla (Granada), Spain, 2Department of Internal Medicine, Hospital Valle de Hebron, Barcelona, Spain, 3Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 4Granada, Spain, 5Department of Dermatology, University of Cologne, Cologne, Germany, 6Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, 7Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, 8Department of Dermatology, Venereology, and Allergologie, HELIOS St. Elisabeth Hospital, Oberhausen, Germany, 9Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 10University of Glasgow, Glasgow, United Kingdom, 11Newcastle University, Musculoskeletal Research Group, Newcastle, United Kingdom, 12Leids Univ Medisch Centrum, Leiden, Netherlands, 13Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 14Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 15Department of Rheumatology, Royal Free Hospital, London, United Kingdom, 16Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 17Musculoskeletal Research Group, University of Manchester, Salford, United Kingdom, 18Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 19Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: genomics, polymorphism, pulmonary complications and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic sclerosis (SSc) is a fibrotic autoimmune disease that represents a clear example of a sex biased immune disorder. The X-chromosome gene IRAK1 has been associated with SSc and systemic lupus erythematosus (SLE), being an interesting candidate to explain this sexual dimorphism. However, IRAK1 is in the same haplotypic block as MECP2 on Xq28, and recent studies suggest that functional genetic variants of the latter locus may explain the association signals with SLE observed in IRAK1. We aimed to evaluate whether the SSc-associated IRAK1 polymorphism rs1059702 (Phe196Ser) is the causal variant of the Xq28 association or whether it reflects another association signal from the nearby MECP2.

Methods: Only women were included in the study. We analysed a total of 3065 SSc patients and 2630 healthy controls from five independent Caucasian cohorts (Spain, USA, Germany, The Netherlands, and UK). A tagging strategy was used to select four taggers that cover all the common genetic variation within MECP2 (r2≥0.8) in the CEU population of the HapMap database (rs3027935, rs17435, rs5987201 and rs5945175). We also included the SSc-associated IRAK1 genetic variant rs1059702. The genotyping was performed with predesigned TaqMan assays. Plink was used for the statistical analyses. P-values were corrected for multiple testing using FDR.

Results: IRAK1 rs1059702 was associated with diffuse cutaneous SSc (dcSSc; PFDR=4.12×10-3, OR=1.27), and trends of association were evident in the global SSc/control (PFDR=0.070, OR=1.13) and anti-topoisomerase positive (ATA+)/control (PFDR=0.087, OR=1.23) comparisons, consistent with previously published data. Similarly, the MECP2 rs17435 variant reached statistical significance after comparing the global disease group and dcSSc subgroup with the control population (PFDR=2.68 x10-3, OR=1.19, and PFDR=5.26×10-4, OR=1.30, respectively). Conditional logistic regression analyses showed that the association of IRAK1 rs1059702 with dcSSc was explained by that of MECP2 rs17435, because only the latter remained significant after conditioned to each other (rs1059702 conditioned P=0.786; rs17435 conditioned P=0.049). However, the analysis of pulmonary fibrosis (PF) data suggested that IRAK1 rs1059702 was consistently associated with this feature, since statistical significance was observed when comparing PF+ vs controls (PFDR=0.039, OR=1.30) and PF+ vs PF- (P=0.025, OR=1.26), but not PF- vs controls (P=0.574, OR=1.04).

Conclusion:

Our data suggest the existence of two independent signals within the Xq28 region, one located in IRAK1 associated with PF, and another in MECP2 associated with dcSSc.


Disclosure:

F. D. Carmona,
None;

M. C. Cénit,
None;

L. M. Díaz-Gallo,
None;

C. P. Simeón,
None;

P. Carreira,
None;

N. Hunzelmann,
None;

G. Riemekasten,
None;

T. Witte,
None;

A. Kreuter,
None;

J. H. Distler,
None;

P. Shiels,
None;

J. M. van Laar,
None;

A. Schuerwegh,
None;

M. C. Vonk,
None;

A. Voskuyl,
None;

C. Fonseca,
None;

C. Denton,
None;

A. Herrick,
None;

F. C. Arnett,
None;

F. K. Tan,
None;

S. Assassi,
None;

T. R. D. J. Radstake,
None;

M. D. Mayes,
None;

J. Martin,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-association-of-irak1-and-mecp2-with-specific-systemic-sclerosis-phenotypes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology